Recently three ATMPs based on HSPC-GT have been approved for the EU market for the treatment of Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID), beta thalassemia and metachromatic leukodystrophy (MLD), respectively2. Here, ADA is linked to severe combined immunodeficiency.